Current Issue : April-June Volume : 2025 Issue Number : 2 Articles : 5 Articles
This review presents current opinions on an uncommon condition called catamenial pneumothorax (CP), which is usually associated with thoracic endometriosis syndrome (TES). TES is characterized by the presence of endometriotic lesions in pleura and lung parenchyma and presents with various clinical signs and symptoms, including catamenial pneumothorax. Their diagnosis is often delayed. Pulmonary endometric lesions, however, often detected in patients with hemothorax and hemoptysis, may be absent in a proportion of cases of pneumothorax. The typical presentation of CP includes signs and symptoms of pneumothorax, which occur along with menstruation, most commonly around 24 h before and 48–72 h after its onset. However, they may not occur during every menstrual cycle. Suggestive CP lesions on conventional radiography (RTG) include pneumoperitoneum accompanying right-sided pneumothorax, lung opacities, pleural effusion, and nodular infiltrates. Chest and abdomen computed tomography (CT), particularly contrast-enhanced, may additionally show pneumoperitoneum and diaphragmatic lesions. The management of CP includes supportive treatment of acute symptoms and causal treatment to prevent recurrent disease. This article presents the pathophysiology of CP, an overview of the diagnostic methods, and the current therapeutic approaches. The necessity for a multidisciplinary approach to the diagnosis of CP and to the choice of the best treatment modality is underlined (promising new therapeutic options are also mentioned); however, international guidelines are still missing....
Background: Respiratory viral infections (RVIs) exhibit seasonal patterns influenced by biological, ecological, and climatic factors. Weather variables such as temperature, humidity, and wind impact the transmission of droplet-borne viruses, potentially affecting disease severity. However, the role of climate in predicting complications in pediatric RVIs remains unclear, particularly in the context of climate-change-driven extreme weather events. Methods: This retrospective cohort study analyzed 1610 hospitalization records of children (0–18 years) with lower respiratory tract infections in Rome, Italy, between 2018 and 2023. Viral pathogens were identified using nasopharyngeal molecular testing, and weather data from the week preceding hospitalization were collected. Several machine learning models were tested, including logistic regression and random forest, comparing the baseline (demographic and clinical) models with those including climate variables. Results: Logistic regression showed a slight improvement in predicting severe RVIs with the inclusion of weather variables, with accuracy increasing from 0.785 to 0.793. Average temperature, dew point, and humidity emerged as significant contributors. Other algorithms did not demonstrate similar improvements. Conclusions: Climate variables can enhance logistic regression models’ ability to predict RVI severity, but their inconsistent impact across algorithms highlights challenges in integrating environmental data into clinical predictions. Further research is needed to refine these models for use in reliable healthcare applications....
Current epidemiological data on interstitial lung disease (ILD) are still poor. The principal cause of the discordant data is associated with a heterogeneous group of respiratory diseases that includes a large number, about 200 families, with low frequency, distinct and sometimes unknown etiology, and different progression. In fact, some conditions spontaneously resolve, whereas others, such as IPF and most non-IPF ILDs, progress to respiratory failure and death despite treatment. Furthermore, epidemiological data are limited. The scope of the narrative review is to report ILD incidence and prevalence in registries from different countries in the last three decades. We identified 20 ILD registries (17 prospective and 3 retrospective) from major countries in Europe (n = 10), Asia (n = 7), North America (n = 2), and Oceania (n = 1). Significant discrepancies in ILD and ILD subtype prevalence and incidence among countries are reported in registries. These discrepancies could be determined by different ethnicities and socioeconomic conditions as well as by updates in disease diagnosis and classification. ILD epidemiological registries are progressively ameliorating through better adherence to updated guidelines and classification codes. An accurate and definite diagnosis and compilation of ILD epidemiological registries will be useful for a more precise monitoring of disease progression and treatment. Future research to identify the populations with the highest risk factors, including genetic and molecular studies, and implementation of disease progression scores are needed to improve ILD clinical assessment....
Lung cancer is a leading cause of brain metastases (BMs), with 10–20% of patients with non-small cell lung cancer (NSCLC) presenting with BMs at diagnosis and 25–50% developing them over the course of their disease. Historically, BMs have posed significant therapeutic challenges, partly due to the blood brain barrier (BBB), which restricts drug penetration to the central nervous system. Consequently, BMs were initially managed with local treatments, including surgical resection, stereotactic radiosurgery, and whole brain radiation therapy. In recent years, however, systemic treatments for BMs have advanced significantly, particularly with the development of molecularlytargeted therapies and immunotherapies. The discovery of driver mutations and the development of novel tyrosine kinase inhibitors (TKIs) have yielded encouraging intracranial responses in NSCLC patients with actionable genetic alterations (e.g., EGFR, ALK, ROS1). Genomic profiling has also suggested genetic heterogeneity between BMs and primary sites. Immunotherapies, alone or in combination with other treatments, have demonstrated promising results in NSCLC with BMs, although most clinical trials have included only selected patients with asymptomatic or previously treated BMs. In this review, we discuss the molecular and immune characteristics of NSCLC with BMs, analyze intracranial efficacy findings from clinical trials, and explore treatment strategies for lung cancer patients with BMs....
Background: Understanding PIK3CA mutations and co-mutations in non-small cell lung carcinoma (NSCLC) is critical to developing personalized treatment strategies. Therefore, this study aims to investigate PIK3CA mutations and the accompanying somatic variations in NSCLC. Methods: This retrospective study included 98 patients over 18 years of age who were diagnosed with NSCLC, operated on, and referred to the Molecular Pathology Laboratory between January 2019 and June 2024 for next-generation sequencing panel tests and ALK-ROS1 FISH analysis. Results: All patients were found to carry PIK3CA mutations. Among the 98 NSCLC patients analyzed, 16 (16.33%) were female and 82 (83.67%) were male. The average age of the patients was 64.53 ± 9.63 years, with an age range of 38–84 years, and the majority were 50 years or older. Of the cases, 51 presented the adenocarcinoma subtype, while the remaining 47 showed the squamous cell carcinoma subtype. A smoking history was present in 77 (78.57%) patients, while 21 (21.43%) had no smoking history. The most frequently detected pathogenic or likely pathogenic PIK3CA variations were c.1633G>A p.E545K (32.65%), c.1624G>A p.E542K (11.22%), c.3140A>G p.H1047R (11.22%), c.3140A>T p.H1047L (5.10%), c.1357G>C p.E453Q (4.08%), and c.3143A>G p.H1048R (2.04%). The top 10 mutations that most commonly accompanied PIK3CA variations were KRAS, NF1, TP53, EGFR, PTEN, BRAF, KIT, CDKN2A, SMARCA4, and ATM mutations, respectively. Conclusions: PIK3CA variations, along with other gene variations, may influence cancer progression and thus may play a crucial role in the determination of targeted treatment strategies....
Loading....